Compare USFD & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USFD | DGX |
|---|---|---|
| Founded | 2007 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0B | 23.2B |
| IPO Year | 2016 | 1996 |
| Metric | USFD | DGX |
|---|---|---|
| Price | $102.35 | $235.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | $103.64 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 2.4M | 1.0M |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.82% |
| EPS Growth | ★ 45.54 | 13.78 |
| EPS | 0.52 | ★ 5.08 |
| Revenue | ★ $39,424,000,000.00 | $11,035,000,000.00 |
| Revenue This Year | $7.63 | $7.53 |
| Revenue Next Year | $3.92 | $3.77 |
| P/E Ratio | $196.42 | ★ $46.30 |
| Revenue Growth | 4.08 | ★ 11.78 |
| 52 Week Low | $69.88 | $166.76 |
| 52 Week High | $105.17 | $240.13 |
| Indicator | USFD | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 63.70 | 76.28 |
| Support Level | $88.34 | $190.42 |
| Resistance Level | $105.17 | N/A |
| Average True Range (ATR) | 2.82 | 6.79 |
| MACD | -0.04 | 2.67 |
| Stochastic Oscillator | 92.04 | 88.69 |
US Foods is a leading domestic foodservice distributor, generating $39 billion in sales in fiscal 2025 and capturing a 10% share of the fragmented industry. The firm sells and distributes more than 350,000 food and nonfood products to about 250,000 customer locations, including independent restaurants (33% of fiscal 2025 sales), chain restaurants (23%), healthcare and hospitality clients (27%), and other end markets (17%), largely consisting of education and government contracts. US Foods also operates 98 cash-and-carry locations under the Chef'Store banner. The firm's physical network spans 76 distribution facilities and 14 broadline production centers.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.